Related Experiment Video
Updated: Aug 26, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
Keelan Z Guiley1, Kevan M Shokat1
1Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California.
Abstract:
The transcription factor and tumor suppressor protein p53 is the most frequently mutated and inactivated gene in cancer. Mutations in p53 result in deregulated cell proliferation and genomic instability, both hallmarks of cancer. There are currently no therapies available that directly target mutant p53 to rescue wild-type function. In this study, we identify covalent compsounds that selectively react with the p53 somatic mutant cysteine Y220C and restore wild-type thermal stability.
Significance:
The tumor suppressor p53 is the most mutated gene in cancer, and yet no therapeutics to date directly target the mutated protein to rescue wild-type function. In this study, we identify the first allele-specific compound that selectively reacts with the cysteine p53 Y220C to rescue wild-type thermal stability and gene activation. See related commentary by Lane and Verma, p. 14. This article is highlighted in the In This Issue feature, p. 1.
Insights
Researchers discovered a novel compound that targets the mutated p53 protein (tumor suppressor protein 53) by selectively reacting with a specific cysteine. This approach aims to restore the normal function of p53, a critical gene in cancer.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The p53 protein is a crucial tumor suppressor frequently inactivated in various cancers.
- Mutations in p53 lead to uncontrolled cell growth and genomic instability, key cancer characteristics.
- Current therapies do not directly address mutant p53 to restore its wild-type function.
Purpose of the Study:
- To identify compounds that can selectively target and react with mutant p53.
- To develop a therapeutic strategy that rescues wild-type p53 function.
Main Methods:
- Screening for covalent compounds that interact with the p53 Y220C mutant.
- Assessing the ability of identified compounds to restore wild-type p53 thermal stability and gene activation.
Main Results:
- Identification of the first allele-specific compound targeting the p53 Y220C mutation.
- Demonstration that the compound selectively reacts with mutant cysteine Y220C.
- Restoration of wild-type thermal stability and gene activation of p53.
Conclusions:
- This study presents a promising therapeutic strategy for cancers with p53 Y220C mutations.
- The identified compound represents a potential first-in-class therapeutic targeting mutant p53.
- Further development could lead to novel treatments for a significant proportion of human cancers.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Negative Regulator Molecules
Spontaneous and Induced Mutations

